|
1
|
Xu XX, Zhou JS, Yuan SH, Yu H and Lou HM:
Distribution of HPV genotype in invasive cervical carcinoma and
cervical intraepithelial neoplasia in Zhejiang province, Southeast
China: Establishing the baseline for surveillance. Int J Environ
Res Public Health. 12:10794–10805. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Magaldi TG, Almstead LL, Bellone S,
Prevatt EG, Santin AD and DiMaio D: Primary human cervical
carcinoma cells require human papillomavirus E6 and E7 expression
for ongoing proliferation. Virology. 422:114–124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Than NG, Romero R, Balogh A, Karpati E,
Mastrolia SA, Staretz-Chacham O, Hahn S, Erez O, Papp Z and Kim CJ:
Galectins: Double-edged swords in the cross-roads of pregnancy
complications and female reproductive tract inflammation and
neoplasia. J Pathol Transl Med. 49:181–208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu H, Zhang S, Zhang R and Zhang L: The
role of VEGF-C/D and Flt-4 in the lymphatic metastasis of
early-stage invasive cervical carcinoma. J Exp Clin Cancer Res.
28:982009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Markowska AI, Jefferies KC and Panjwani N:
Galectin-3 protein modulates cell surface expression and activation
of vascular endothelial growth factor receptor 2 in human
endothelial cells. J Biol Chem. 286:29913–29921. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Punt S, Thijssen VL, Vrolijk J, de Kroon
CD, Gorter A and Jordanova ES: Galectin-1, −3 and −9 expression and
clinical significance in squamous cervical cancer. PLoS One.
10:e01291192015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ebrahim AH, Alalawi Z, Mirandola L,
Rakhshanda R, Dahlbeck S, Nguyen D, Jenkins M, Grizzi F, Cobos E,
Figueroa JA, et al: Galectins in cancer: Carcinogenesis, diagnosis
and therapy. Ann Transl Med. 2:882014.PubMed/NCBI
|
|
8
|
Liu X, Yang WT and Zheng PS: Msi1 promotes
tumor growth and cell proliferation by targeting cell cycle
checkpoint proteins p21, p27 and p53 in cervical carcinomas.
Oncotarget. 5:10870–10885. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pavlides SC, Huang KT, Reid DA, Wu L,
Blank SV, Mittal K, Guo L, Rothenberg E, Rueda B, Cardozo T, et al:
Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth
stimulation and degradation of nuclear p27kip1: Therapeutic
potential for endometrial cancer. Endocrinology. 154:4030–4045.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu XL and Zheng PS: Undifferentiated
embryonic cell transcription factor-1 (UTF1) inhibits the growth of
cervical cancer cells by transactivating p27Kip1. Carcinogenesis.
34:1660–1668. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kovak MR, Saraswati S, Schoen DJ and
Diekman AB: Investigation of galectin-3 function in the
reproductive tract by identification of binding ligands in human
seminal plasma. Am J Reprod Immunol. 72:403–412. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao Q, Guo X, Nash GB, Stone PC, Hilkens
J, Rhodes JM and Yu LG: Circulating galectin-3 promotes metastasis
by modifying MUC1 localization on cancer cell surface. Cancer Res.
69:6799–6806. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oka N, Nakahara S, Takenaka Y, Fukumori T,
Hogan V, Kanayama HO, Yanagawa T and Raz A: Galectin-3 inhibits
tumor necrosis factor-related apoptosis-inducing ligand-induced
apoptosis by activating Akt in human bladder carcinoma cells.
Cancer Res. 65:7546–7553. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peng W, Wang HY, Miyahara Y, Peng G and
Wang RF: Tumor-associated galectin-3 modulates the function of
tumor-reactive T cells. Cancer Res. 68:7228–7236. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang W, Guo H, Geng J, Zheng X, Wei H, Sun
R and Tian Z: Tumor-released Galectin-3, a soluble inhibitory
ligand of human NKp30, plays an important role in tumor escape from
NK cell attack. J Biol Chem. 289:33311–33319. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mitsuhashi A, Suzuka K, Yamazawa K, Matsui
H, Seki K and Sekiya S: Serum vascular endothelial growth factor
(VEGF) and VEGF-C levels as tumor markers in patients with cervical
carcinoma. Cancer. 103:724–730. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cui N, Yang WT and Zheng PS: Slug inhibits
the proliferation and tumor formation of human cervical cancer
cells by up-regulating the p21/p27 proteins and down-regulating the
activity of the Wnt/β-catenin signaling pathway via the
trans-suppression Akt1/p-Akt1 expression. Oncotarget.
7:26152–26167. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang K-T, Pavlides SC, Lecanda J, Blank
SV, Mittal KR and Gold LI: Estrogen and progesterone regulate
p27kip1 levels via the ubiquitin-proteasome system: Pathogenic and
therapeutic implications for endometrial cancer. PLoS One.
7:e460722012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou N, Yuan S, Wang R, Zhang W and Chen
JJ: Role of dual specificity tyrosine-phosphorylation-regulated
kinase 1B (Dyrk1B) in S-phase entry of HPV E7 expressing cells from
quiescence. Oncotarget. 6:30745–30761. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rath SL and Senapati S: Mechanism of p27
unfolding for CDK2 reactivation. Sci Rep. 6:264502016. View Article : Google Scholar : PubMed/NCBI
|
